Sponsored By:

5 Triply Tempting Blue-Chip Stocks to Buy

Earnings, dividend hikes & surges make these the belles of the ball

      View All  

Abbott Labs

abbottLogo e1293650852771 5 Triply Tempting Blue Chip Stocks to BuyIn April, drugmaker Abbott Labs (NYSE:ABT) reported better-than-expected quarterly sales and earnings that were largely due to strong demand for its Humira arthritis drug. The company earned $1.24 billion, or 78 cents per share, in the first quarter, up from $864 million, or 55 cents per share, the prior year. Excluding special items, Abbott earned $1.03 per share, which beat Wall Street estimates for $1. A couple months earlier, Abbott upped the dosage on its dividend by 6.25% to 51 cents per share. Investors have rewarded Abbott’s solid performance by bidding the stock up about 10% year-to-date.

Abbott is one of the best drugmakers out there, with a host of moneymaking products out now, and many more in the pipeline — which should ensure big numbers for many quarters to come.


Article printed from InvestorPlace Media, http://investorplace.com/2012/05/5-triply-tempting-blue-chip-stocks-to-buy/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.